LIPO-5Other Names: ANRS HIV-LIPO-5, HIV-LIPO-5 Drug Class: Therapeutic Vaccines Organization: French National Agency for Research on AIDS and Viral Hepatitis (ANRS) Phase of Development: LIPO-5 is in Phase II development as a therapeutic HIV vaccine. (LIPO-5 is also being studied as a preventive HIV vaccine.)
(Compound details obtained from ANRS: HIV Vaccine Research Programme,1 AIDS article,2 and Treatment Action Group 2017 Pipeline Report3)
What is an investigational vaccine?
To learn more about investigational vaccines and investigational drugs, read the What is an Investigational HIV Drug? fact sheet.
What is LIPO-5?
LIPO-5 is an investigational vaccine that is being studied as a therapeutic vaccine for HIV.3 Ais a type of vaccine that’s designed to improve the body’s to HIV in a person who is already infected with HIV.4
HIV researchers are developing and testing therapeutic vaccines to:
- Slow down the progression of HIV .
- Eliminate the need for (ART) while still maintaining undetectable levels of HIV. (ART is the recommended treatment for HIV infection and involves using a combination of different HIV medicines to prevent HIV from replicating.)
- Use in combination with HIV medicines to eliminate all HIV from the body.
The AIDSinfo fact sheet What is a Therapeutic HIV Vaccine? has more information on therapeutic HIV vaccines.5,6
Besides being studied as a therapeutic HIV vaccine, researchers are also investigating the LIPO-5 vaccine to see if it can prevent HIV infection in people who do not have the.1,7 This vaccine record focuses on the study of LIPO-5 as a therapeutic vaccine.
How are clinical trials of investigational vaccines conducted?
Clinical trials are conducted in phases. Each phase has a different purpose and helps researchers answer different questions.8
- Phase I trials: Researchers test an investigational vaccine in a small group of people (20–80) for the first time. The purpose is to evaluate its safety, identify side effects, and determine if the vaccine produces an immune response in the body.
- Phase II trials: The investigational vaccine is administered to a larger group of people (100–300). Researchers further evaluate the vaccine’s safety and ability to produce an immune response in the body. Some effectiveness data on the health benefits of the vaccine may also be collected.
- Phase III trials: The investigational vaccine is administered to large groups of people (1,000–3,000) to confirm its effectiveness, monitor side effects, compare it with standard or equivalent treatments, and collect information that will allow the investigational vaccine to be used safely.8,9
Some clinical trials are categorized as “a” or “b,” such as “Phase Ia” or “Phase IIb.” These different subphases typically mean that a study is researching certain types of information or using a certain type of participant population.
In what phase of testing is LIPO-5?
As a therapeutic HIV vaccine, LIPO-5 is currently being studied in a Phase II clinical trial.3
What are some studies on LIPO-5?
LIPO-5 therapeutic HIV vaccine
Study Names: VRI02/ANRS 149 LIGHT; NCT01492985
Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral (Inserm-ANRS)
Status: This study is ongoing, but not recruiting participants.
- Participants are adults with HIV who have no symptoms of HIV infection and who have been on ART for at least 18 months.
- Participants have had levels of less than 50 copies/mL for the past 6 months. (Viral load is the amount of HIV in a blood sample.) Participants also have viral load levels of less than 50 copies/mL at a study visit during Week 3.
- Participants have had CD4 counts of at least 600 cells/mm3 for the previous 6 months. (A is a laboratory test that measures the number of CD4 cells—a type of immune cell—in a sample of blood and is an important indicator of immune function.) Participants also have CD4 counts of at least 600 cells/mm3 at a study visit during Week 3. A participant has never had a CD4 count lower than 300 cells/mm3 while on ART.
For more details on this study, see the Health Professional version.
What side effects might LIPO-5 cause?
One goal of HIV research is to identify new drugs that have fewer side effects. Early data from the VRI02/ANRS 149 LIGHT study (NCT01492985) was reported in a press release from the GTU-MultiHIV B manufacturers. The data suggest that no major side effects occurred in the participants receiving GTU-MultiHIV B and LIPO-5.10-12
Because LIPO-5 is still being studied, information on possible side effects of the vaccine is not complete. As testing of LIPO-5 continues, additional information on possible side effects will be gathered.
Where can I get more information about clinical trials studying LIPO-5?
More information about LIPO-5-related research studies is available from the AIDSinfo database of study summaries. Click on the title of any trial in the list to see the ClinicalTrials.gov trial summary and more information about the study.
How can I find more information about participating in a clinical trial?
Participating in a clinical trial can provide benefits. For example, a volunteer participant can benefit from new research treatments before they are widely available. Participants also receive regular and careful medical attention from a research team that includes doctors and other health professionals. However, clinical trials may also involve risks of varying degrees, such as unpleasant, serious, or even life-threatening side effects from the treatment being studied.8
Your health care provider can help you decide whether participating in a clinical trial is right for you. For more information, visit NIH Clinical Research Trials and You.
- ANRS HIV Vaccine Network. ANRS HIV Vaccine Research Programme. December 2010. Available at: http://www.anrs.fr/content/download/1539/10054/file/hiv. Last accessed on October 20, 2016.
- Salmon-Céron D, Durier C, Desaint C, et al. Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. AIDS. 2010 Sep 10; 24(14): 2211-23. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20625264. Last accessed on November 30, 2017.
- Frick M, Gaudino A, Harrington M, et al. Treatment Action Group. 2017 pipeline report. July 2017. Available at: http://www.pipelinereport.org/sites/default/files/2017%20Pipeline%20Report%20Final.pdf. Last accessed on November 30, 2017. [Archived at WebCite]
- The History of Vaccines website. The development of HIV vaccines. Available at: https://www.historyofvaccines.org/content/articles/development-hiv-vaccines. Last accessed on November 30, 2017.
- Smith PL, Tanner H, Dalgleish A. Developments in HIV-1 immunotherapy and therapeutic vaccination. F1000Prime Rep. 2014 Jun 2; 6:43. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047951/. Last accessed on November 30, 2017.
- Graziani GM and Angel JB. Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions. J Int AIDS Soc. 2015; 18(1): 20497. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641978/. Last accessed on November 30, 2017.
- French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS). Phase I/II open-label randomized multicenter trial to assess immunogenicity and safety of 4 prime-boost combinations of HIV vaccine candidates (MVA HIV-B/ LIPO-5; LIPO-5/MVA HIV-B; GTU®-MultiHIV B / LIPO-5; GTU®-MultiHIV B/MVA HIV-B) in healthy volunteers at low risk of HIV infection. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on January 2, 2014. NLM Identifier: NCT02038842. Available at: https://clinicaltrials.gov/ct2/show/NCT02038842. Last accessed on November 30, 2017.
- National Institutes of Health (NIH). NIH clinical research trials and you. Available at: https://www.nih.gov/health-information/nih-clinical-research-trials-you. Last accessed on November 30, 2017.
- Hudgens MG, Gilbert PB, Self SG. Endpoints in vaccine trials. Stat Methods Med Res. 2004; 13: 1-26. Available at: http://faculty.washington.edu/peterg/Vaccine2006/articles/HudgensGilbertSelfSMMR.pdf. Last accessed on November 30, 2017.
- French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS). Evaluation of a therapeutic immunization strategy associating a DNA vaccine (GTU-MultiHIV B) followed by a lipopeptide vaccine (LIPO-5) in the control of viral replication following antiretroviral treatment interruption in HIV-1 infected patients with a CD4 cell count ≥ 600/mm3. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on November 24, 2011. NLM Identifier: NCT01492985. Available at: https://clinicaltrials.gov/ct2/show/NCT01492985. Last accessed on November 30, 2017.
- Ghosn J, Palich R, Chaillon A, et al. Viral rebound in semen after treatment interruption in a HIV therapeutic vaccine double-blind trial (VRI02/ANRS149-LIGHT). Abstract presented at: International AIDS Society (IAS) Conference on HIV Science; July 23-26, 2017; Paris, France. Abstract TUPDB0105. Available at: http://programme.ias2017.org/Abstract/Abstract/3125. Last accessed on November 30, 2017. [Archived at WebCite]
- FIT Biotech Oy: Press Release, dated June 9, 2016. FIT Biotech’s HIV vaccine demonstrated to be safe and well tolerated in two clinical studies. Available at: http://www.fitbiotech.com/tiedote/fit-biotech-oy-fit-biotechs-hiv-vaccine-demonstrated-to-be-safe-and-well-tolerated-in-two-clinical-studies/. Last accessed on November 30, 2017. [Archived at WebCite]
Last Reviewed: November 30, 2017